IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v19y2001i5p483-495.html
   My bibliography  Save this article

The Lifetime Cost of Bipolar Disorder in the US

Author

Listed:
  • Charles Begley
  • John Annegers
  • Alan Swann
  • Christopher Lewis
  • Sharon Coan
  • William Schnapp
  • Lynda Bryant-Comstock

Abstract

Objective: To develop a cost model that estimates the total and per case lifetime cost of bipolar disorder for 1998 incident cases in the US. Study design: Lifetime cost simulation model. Perspective: Societal. Methods: Age- and gender-specific incidence of bipolar disorder in 1998 was estimated by simulation based on existing prevalence data. The course of illness and mental health service cost of 6 clinically defined prognostic groups was estimated based on the research literature and the judgement of panels of experts. Excess cost of general medical care was estimated based on claims data from a large insurer. Indirect cost was projected including excess unemployment and reduced earnings reported in the National Comorbidity Survey. Comorbidity treatment and indirect cost related to alcohol (ethanol) and drug abuse was added based on a National Institute on Drug Abuse study. Results: The present value of the lifetime cost of persons with onset of bipolar disorder in 1998 was estimated at 24 billion US dollars ($US). Average cost per case ranged from $US11 720 for personswith a single manic episode to $US624 785 for persons with nonresponsive/chronic episodes. Conclusion: The model indicates the potential cost savings of preventing a case of bipolar disorder and underscores the importance of achieving a stable outcome in new cases to limit the economic consequences of the disorder. Copyright Adis International Limited 2001

Suggested Citation

  • Charles Begley & John Annegers & Alan Swann & Christopher Lewis & Sharon Coan & William Schnapp & Lynda Bryant-Comstock, 2001. "The Lifetime Cost of Bipolar Disorder in the US," PharmacoEconomics, Springer, vol. 19(5), pages 483-495, May.
    • Handle: RePEc:spr:pharme:v:19:y:2001:i:5:p:483-495
    DOI: 10.2165/00019053-200119050-00004
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-200119050-00004
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/00019053-200119050-00004?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Tatia Woodward & Eskinder Tafesse & Peter Quon & Arthur Lazarus, 2010. "Cost Effectiveness of Adjunctive Quetiapine Fumarate Extended-Release Tablets with Mood Stabilizers in the Maintenance Treatment of Bipolar I Disorder," PharmacoEconomics, Springer, vol. 28(9), pages 751-764, September.
    2. Valentin Marian ANTOHI & Florin Marian BUHOCIU & Daniela Gabriela GLAVAN & Cristina COTOCEL & Mihail Cristian PIRLOG, 2017. "Socio-Economic Costs of Affective Disorders in Romania," Risk in Contemporary Economy, "Dunarea de Jos" University of Galati, Faculty of Economics and Business Administration, pages 579-604.
    3. Valentin Marian ANTOHI & Florin Marian BUHOCIU & Daniela Gabriela GLAVAN & Cristina COTOCEL & Mihail Cristian PIRLOG, 2017. "Socio-Economic Costs of Affective Disorders in Romania," Proceedings RCE 2017, Editura Lumen, vol. 0, pages 579-604, November.
    4. Deborah Schofield & Rupendra Shrestha & Simon Kelly & Lennert Veerman & Robert Tanton & Megan Passey & Theo Vos & Michelle Cunich & Emily Callander, 2014. "Health&WealthMOD2030: A Microsimulation Model of the Long Term Economic Impacts of Disease Leading to Premature Retirements of Australians Aged 45-64 Years Old," International Journal of Microsimulation, International Microsimulation Association, vol. 7(2), pages 94-118.
    5. Greg Plosker, 2012. "Quetiapine," PharmacoEconomics, Springer, vol. 30(7), pages 611-631, July.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:19:y:2001:i:5:p:483-495. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.